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Abstract
DNA-dependent protein kinase (DNA-PK) has been shown to take part in cell cycle regulatory signal transduction and in
the repair of X-ray-induced DNA double-strand breaks. Functional DNA-PK is furthermore needed for the generation of
antigen specificity during lymphocyte maturation. The Ku86 subunit of DNA-PK has been reported to exist in human B
lymphocytes in a truncated form capable of binding to broken DNA but lacking the ability to activate the kinase function of
DNA-PK. In the present work the Ku70 and Ku86 dimer proteins in T and B lymphocytes from human blood donors were
analysed by immunoblotting and were observed apparently to be of full length. Also, nuclear protein extracted from B and
non-B lymphocytes displayed DNA-dependent kinase activity. However, a minor fraction of Ku86 in lymphocytes was
observed to be truncated with a molecular mass of approx. 70 kDa. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
A set of functionally related proteins with an im-
portant role for the cellular response to DNA strand
break formation is commonly referred to as DNA-
dependent protein kinase (DNA-PK), consisting of
two DNA-binding subunits (Ku70 and Ku86) medi-
ating activation of the large 465 kDa kinase catalytic
subunit [1^4]. DNA-PK has been shown to be part
of cell cycle regulatory signal transduction engaging
p53 and ATM (ataxia telangiectasia mutated) [5^9],
and to be part of the repair of DNA double-strand
breaks and UV-induced DNA damage [10^12]. In
addition, in human lymphocytes functional DNA-
PK is needed for CD40 signalling [13] and for the
associated generation of antigen speci¢city during
lymphocyte maturation, due to its involvement in
V(D)J recombination and possibly also in the class
switching of immunoglobulin (Ig) genes [1,2,14].
DNA-PK is constitutively expressed in many hu-
man cell types, and some mechanisms for the regu-
lation of its activity are known. The cutting of DNA
by RAG (recombination-activating genes) at recom-
bination signal sequences in lymphocytes is thought
to be rate limiting for DNA-PK activity during
V(D)J recombination [3]. Another possible mecha-
nism for cellular control of DNA-PK activity is Ku
proteolysis, since Ku86 has been observed in human
B lymphocytes [15], in late-passage human primary
¢broblasts [16] and in the HL60 human promyeloid
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cell line [17] to be truncated with an apparent mo-
lecular mass of approx. 70 kDa. This carboxy-termi-
nal modi¢cation of Ku86 does not prevent its DNA
binding but causes loss of activation of the DNA-PK
catalytic subunit [15,18]. In ¢broblasts this trunca-
tion was shown to occur not until a protease was
brought into contact with Ku during the in vitro
extraction procedure [16].
In the present work B and non-B lymphocytes
were found to have Ku86 protein of apparently full
length, and to display similar levels of DNA-depen-
dent kinase activity. However, truncation of Ku86
and a decline in the amount of intact Ku70 protein
occurred during in vitro blood incubation.
2. Materials and methods
2.1. Cells
Peripheral blood mononuclear cells were isolated
from venous blood of healthy donors by gradient
centrifugation (Lymphoprep, Nycomed, Norway).
A human B lymphoblastoid cell line was established
from peripheral blood by EBV transformation as
described [19].
HeLa cells were from an in-house source and of
unidenti¢ed origin. The human epithelial-like tumour
line HEp2 was from the American Type Culture Col-
lection (ATCC, Manassas, VA) (CCL23). All cells
were cultured in RPMI 1640 (Gibco, UK) supple-
mented with 10% fetal calf serum, 2 mM L-gluta-
mine, 25 mM HEPES and 12 Wg/ml gentamicin.
2.2. Antibodies
Antibodies (Abs) used for Western analysis were
polyclonal goat anti-Ku-70 (SC-1486; reactive with a
C-terminal epitope corresponding to amino acids
590^608) and anti-Ku-86 (SC-1484; reactive with a
C-terminal epitope corresponding to amino acids
710^729) from Santa Cruz Biotechnology (Santa
Cruz, CA); anti-Ku86 (P80, Ab-3; clone S10B1; re-
active with an N-terminal epitope corresponding to
amino acids 8^221) was a mouse monoclonal IgG
from Oncogene (Cambridge, MA); HRP-conjugated
anti-goat and anti-mouse Ig were from Dako (Den-
mark). The epitope speci¢cations are as indicated by
the manufacturers. Abs used for FACS analysis,
anti-HLA-DR FITC and anti-CD3-PE, anti-CD19-
FITC and anti-CD5-PE, and the isotypic controls
MSIgG1-RD1/MSIgG1-FITC were from Beckman-
Coulter. Iron bead-conjugated anti-CD3 and anti-
CD19 Abs for magnetic separation of T and B lym-
phocytes (for positive selection), as well as a kit for
isolation of untouched B cells (i.e. for negative selec-
tion) containing a cocktail of Abs to non-B mono-
nuclear leucocytes (Abs to CD2, CD4, CD11b,
CD16, CD36 and IgE), were from Miltenyi Biotec
(Germany).
2.3. Extraction of nuclear proteins
Immediately following blood sampling, the periph-
eral blood mononuclear cells of healthy donors were
isolated from venous blood by gradient centrifuga-
tion using Lymphoprep. The isolated cells were used
directly for extraction of nuclear proteins following a
modi¢cation of the procedure of Schreiber et al. [20].
Cytoplasmic protein was removed by lysis of pelleted
cells in a neutral pH bu¡er containing 10 mM
HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 0.5% NP-40 and a mixture of proteinase in-
hibitors (Complete, from Roche-Boehringer-Mann-
heim, Germany). Pelleted cell nuclei were then lysed
on ice in a hyperosmolar neutral pH solution with 20
mM HEPES, 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA and 10% Complete. Protein concentration
was determined spectrophotometrically at 540 nm
in 96-well microtitre plates using BCA Protein Assay
Reagents (Pierce, IL). All extracts were stored at
370‡C.
2.4. Isolation of T and B lymphocytes
Peripheral blood mononuclear cells of healthy do-
nors were isolated as described above. Isolation of
T and B lymphocytes was done following the recom-
mendations of the manufacturer (Miltenyi Biotec).
Brie£y, lymphocytes were washed with PBS and ¢l-
tered through a 30 Wm ¢lter. Cells were magnetically
labelled with anti-human-CD19-conjugated iron mi-
crobeads (20 Wl microbeads per 107 cells) for 15 min
at 6^12‡C. The chromatography procedure was per-
formed with a positive selection column (VS plus)
placed in a magnetic ¢eld. For the isolation of
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B cells, the magnetically labelled CD19 positive cells
were retained in the column while the unlabelled cells
ran through. The column was rinsed with 4U3 ml
PBS (pH 7.2) supplemented with 0.5% BSA and
5 mM EDTA. After removal of the column from
the magnetic ¢eld, the magnetically retained CD19
positive cells were eluted with 5 ml of rinsing bu¡er.
The T cells were isolated with the same procedure,
except for using anti-human-CD3-conjugated iron
microbeads. The B lymphocyte negative selection
procedure using a CS column included the retention
in the magnetic column of PBL reacted with a panel
of antibodies to non-B mononuclear leucocytes. A
fraction of the isolated cells was analysed for purity
by £ow cytometry. The isolated T and B cells were
used for preparation of nuclear extract as described
above.
2.5. Flow cytometry
The purity of the isolated T and B cells was ana-
lysed using a Coulter Epics XL-MCL £ow cytometer
(Coulter, Hialeah, FL) equipped with a 488 nm ar-
gon laser for excitation and ¢lters detecting emission
at 515^545 nm (for FITC) and 565^595 nm (for PE).
Background auto£uorescence was monitored for
each sample by analysing cells labelled with dual
colour isotypic non-speci¢c mouse Ig. The mouse
Fig. 1. Purity of isolated B and T lymphocyte subpopulations determined by £ow cytometry. T lymphocytes were positively selected
by anti-CD3-conjugated iron beads and then labelled with anti-CD5-PE plus anti-CD19-FITC. For the positive selection of B lympho-
cytes anti-CD19-conjugated iron beads were used followed by £ow cytometry with anti-HLA-DR-FITC plus anti-CD3-PE. For the
negative selection of B lymphocytes a magnetic bead procedure including a cocktail of non-B lymphocyte antibodies was used, fol-
lowed by £ow cytometry with anti-CD5-PE plus anti-CD19-FITC.
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monoclonal Abs were diluted 1/10 in PBS using 5 Wl
for staining of 0.5^5U106 cells/ml. Isolated cells were
incubated with dual colour Abs in the dark for
30 min at 4‡C. The purity of the T and B popula-
tions was determined using anti-CD19-FITC/anti-
CD5-PE and anti-HLA-DR-FITC/anti-CD3-PE con-
jugated Abs.
2.6. Western blot analysis
Fractions of the extracted nuclear protein (10 Wg)
were pretreated for 10 min at 70‡C before loading
onto a NuPAGE 7% Tris-acetate pre-cast gel (1.0
mmU12 wells, from Novex, Groningen, Nether-
lands) and electrophoresis for 1.5 h, 120 V and
then transfer by electroblotting to a polyvinylidene
£uoride (PVDF) membrane for 1.5 h, 30 V. A pre-
stained size marker (Novex SeeBlue pre-stained stan-
dard) was included in each run. After blocking with
bu¡er (TBS containing 0.05% Tween 20 and 1.5%
ovalbumin) the membranes were incubated for 1 h
at room temperature with the following primary
antibodies: mouse anti-Ku86 diluted 1/1000, goat
anti-Ku86 diluted 1/2000 and goat anti-Ku70 diluted
1/2000. Subsequently, blots were incubated with
HRP-conjugated anti-mouse diluted 1/2000 and
HRP-conjugated anti-goat diluted 1/4000 for 1 h at
room temperature, under gentle agitation. The blots
were developed using the enhanced chemilumines-
cence method (ECL from Amersham-Pharmacia).
2.7. Analysis of DNA-PKcs phosphorylating function
The phosphorylating function of DNA-PK was
measured using a synthetic peptide containing a con-
sensus p53 phosphorylation site (EPPLSQEA-
FADLWKK; Promega, USA) as substrate. 5 Wg of
nuclear protein extract was mixed with 0.1 Wl of
[Q-33P]ATP (1000^3000 Ci/mmol; Amersham-Phar-
macia, UK), 0.25 mM ATP and 7.5 Wg of peptide
substrate in a HEPES bu¡er (25 mM HEPES pH
7.6, 50 mM KCl, 10 mM MgCl2, 0.2 mM EGTA,
1 mM DTT and 4% glycerol) in the presence or
absence of 1 Wg of sonicated calf thymus DNA. After
incubation at 37‡C for 20 min the reactions were
stopped with 30% acetic acid and spotted onto
squares of phosphocellulose paper (P81, Whatman,
Germany). After washing repeatedly with acetic acid
(15%) and distilled water, bound radioactivity was
determined by liquid scintillation counting. All sam-
ples were analysed in triplicate.
3. Results
3.1. Full length Ku in both T and B lymphocytes
Highly enriched T and B lymphocyte subpopula-
tions were isolated by a positive selection procedure
including incubation of peripheral blood mononu-
clear cells with iron microbeads conjugated with
anti-CD3 or anti-CD19 followed by magnetic col-
umn chromatography (Fig. 1). In addition, B lym-
phocytes were isolated with a negative magnetic
chromatography procedure, in order to minimize
manipulation of the selected cells such as labelling
with antibodies and binding to the magnetic column.
As determined by £ow cytometry using anti-CD5
and anti-HLADR, respectively, the positive selection
strategy yielded a purity of 97.5% for the T lympho-
cytes and 99.6% for the B lymphocytes. Although the
negative selection, as expected, was less e⁄cient, it
resulted in a cell population with 92.7% CD19
B lymphocytes (i.e. 87.1% plus 5.6% CD5 B-1 lym-
phocytes), with 1.7% T lymphocytes and some un-
identi¢ed cells (Fig. 1).
Crude nuclear protein preparations were made,
separated by denaturing SDS-PAGE and immuno-
blotted in order to semi-quantitate the cellular con-
tent of Ku protein. Both B and T lymphocytes could
be observed to contain full length Ku70 and Ku86
protein in the nucleus (Fig. 2a^g). B and T lympho-
Fig. 2. Full length Ku70 and Ku86 in B and T lymphocytes, followed by incubation-dependent Ku degradation in both B and T lym-
phocytes. After incubation of the blood at room temperature for the indicated times, the lymphocyte subpopulations were isolated by
magnetic bead chromatography using positive and negative selection, as indicated. Nuclear protein was then extracted and immuno-
blotting performed as indicated with a monoclonal Ab to an amino-terminal Ku86 epitope, polyclonal Ab to a carboxy-terminal
Ku86 epitope, and polyclonal anti-Ku70 Ab. The arrow indicates the position of a molecular mass 71 kDa marker.
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cytes isolated by a positive selection magnetic bead
procedure (Fig. 2a^c for B cells, and Fig. 2e^g for
T cells), as well as from negative selection of B lym-
phocytes (Fig. 2d) show no di¡erence in the evidence
of full length Ku protein due to lymphocyte type or
the type of selection. No di¡erence could be found in
the Ku86 full length size between lymphocytes and
human cell lines (one B lymphoid line and two epi-
thelial lines) (Fig. 2h). The monoclonal Ku86 Ab
reactive with an amino-terminal epitope revealed
one full length Ku86 band and a lower approx. 70
kDa molecular mass band (Fig. 2a,d,e,h). The frac-
tion of Ku86 protein appearing at this lower molec-
ular mass band was higher in the non-incubated PBL
(time 0 h, ¢rst lane, Fig. 2a,d,e) as compared with
both of the B and T lymphocyte populations (time
0 h, third lane, Fig. 2a,e and second lane, Fig. 2d),
and was found to become increased in PBL as well as
in both B and T lymphocytes upon incubation of
blood for 24^48 h (Fig. 2a,e). The location of the
truncation to the C-terminus was supported by the
observation that the goat polyclonal Ab recognizing
a C-terminal Ku86 epitope produced only one full
length band (Fig. 2b,f). Similar results for Ku86
truncation were obtained with T and B lymphocytes,
and irrespective of the type of selection procedure
employed. Some cellular modi¢cation of Ku70 is in-
dicated by the decrease in band intensity observed
with anti-Ku70 in protein extracts of cells from in-
cubated blood, although there was no sign of any
relatively low molecular mass band with the anti-
Ku70 Ab (Fig. 2c,g).
3.2. DNA-dependent kinase activity in
T and B lymphocytes
In order to document the function of the full
length Ku heterodimers, the ability of Ku protein
to activate the kinasing function of DNA-PKcs was
assayed. B lymphocytes were negatively isolated us-
ing a depletion column. The purity of B cells was
determined with anti-CD5 and anti-CD19 Abs as
shown in Fig. 1. Nuclear protein was extracted and
the in vitro DNA-dependent phosphorylation was
determined using a synthetic p53 peptide containing
a DNA-PKcs-speci¢c phosphorylation site. A clear
DNA-dependent incorporation of radiolabelled
phosphate was observed in the selected cell popula-
Fig. 3. DNA-dependent kinase activity in B lymphocytes. The in vitro phosphorylation by nuclear protein extracts (5 Wg) of a syn-
thetic p53 peptide fragment, in the presence of double-stranded linear DNA (dsDNA, as indicated) and [Q-33P]ATP, was determined.
Results from two independent B lymphocyte isolation experiments, each performed with and without addition of dsDNA, are shown.
B lymphocytes were isolated by a negative selection magnetic bead procedure. Non-B PBL denotes magnetic bead-labelled PBL re-
maining in the column after elution of the unlabelled B lymphocytes. PBL refers to the cells not subjected to any magnetic bead sepa-
ration procedure, and PBL 48 h indicates PBL isolated from blood incubated for 48 h at room temperature. The HEp2 cells were
grown under optimal conditions. All samples were analysed in triplicate.
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tion containing 92% B lymphocytes. This activity
level was similar to that of (i) the epithelial HEp2
line, (ii) non-selected PBL, as well as (iii) the non-B
cells bound to the magnetic separation column con-
taining 80% T lymphocytes (£ow cytometry results
not shown). Similar results were obtained in two in-
dependent experiments, based on blood from two
healthy individuals. No DNA-dependent kinase ac-
tivity could be detected in PBL from 48 h incubated
blood (Fig. 3); immunoblotting of this PBL nuclear
extract showed lack of full length Ku86, but pre-
sented a band corresponding to the truncated Ku86
form, indicating that full length Ku86 is needed for
this kinase activity (immunoblotting results not
shown).
4. Discussion
Our results con¢rm the previous observation of
truncated Ku86 in human B lymphocytes [15] and
also extend it by showing that under as yet unde¢ned
conditions virtually all Ku86 of B cells can exist as
an apparently full length form. The lower migration
Ku86 form was seen in non-incubated PBL together
with virtual lack of this truncated form in the puri-
¢ed B and T lymphocytes. This discrepancy may be
due to the presence of truncated Ku86 in monocytes.
However, our collected experience from analysis of
PBL from a large number of healthy individuals sug-
gests no correlation with the size of the monocyte
population. Instead, the magnetic bead procedure
employed for the isolation of B and T lymphocytes
may select for cells being relatively una¡ected by the
in vitro handling of the blood, and thus reduce the
proportion of cells with truncated Ku86. Further-
more, indicating the similarity between B lympho-
cytes and other cell types in DNA-PK characteristics,
we observed the B lymphocyte full length Ku86 to be
functionally equivalent to Ku86 isolated from other
cell types, i.e. by demonstrating its capacity to acti-
vate the catalytic subunit of DNA-PK.
Our ¢nding of the appearance during in vitro in-
cubation of blood in lymphocytes of truncated Ku86
suggests that the ¢ndings of Muller et al. [15] of a
lack of full length Ku86 in B lymphocytes may have
been in£uenced by proteolysis during the in vitro
procedure of B lymphocyte isolation. Interestingly,
it was demonstrated recently that in human primary
¢broblasts, although no truncated Ku86 can be de-
tected in intact cells, the exposure during the protein
extraction procedure of cellular Ku86 to a serine
protease appearing in late-passage ¢broblasts leads
to in vitro Ku86 truncation [13]. Since the degraded
forms of Ku86 reported in various cell types by dif-
ferent workers [13,15^17] have not yet been charac-
terized in detail, it is not known whether they are
identical to each other or result from a speci¢c pro-
teolytic event. Nevertheless, it may be speculated that
the Ku86 truncation observed by us is part of a post-
translational cellular Ku regulatory mechanism,
rather than to merely re£ect a general disintegration
of lymphocyte protein in vivo and/or in vitro. Cer-
tainly, considering the role of DNA-dependent pro-
tein kinase (including the Ku subcomponents) in a
number of cellular processes including complex sig-
nal transduction engaging p53 and ATM in£uencing
cell cycle progression and apoptosis [3,5^9], mecha-
nisms for the control of Ku activity are likely to have
evolved in human cells.
In summary, the present work provides evidence
of normal Ku protein in human peripheral blood
B lymphocytes.
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